Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69(1):7–34

Article  PubMed  Google Scholar 

Sher T, Dy GK, Adjei AA (2008) Small cell lung cancer. Mayo Clin Proc 83(3):355–367

Article  CAS  PubMed  Google Scholar 

Morgensztern D, Ng SH, Gao F et al (2010) Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol 5(1):29–33

Article  PubMed  Google Scholar 

König D, Savic Prince S, Rothschild SI (2021) Targeted therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An update on treatment of the most important actionable oncogenic driver alterations. Cancers (Basel) 13(4):804

Article  PubMed  Google Scholar 

Baggstrom MQ, Stinchcombe TE, Fried DB et al (2007) Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. J Thorac Oncol 2(9):845–853

Article  PubMed  Google Scholar 

Reck M, Rodríguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus Chemotherapy for PD-L1-Positive non-small-cell Lung Cancer. N Engl J Med 375(19):1823–1833

Article  CAS  PubMed  Google Scholar 

Mok TSK, Wu YL, Kudaba I et al (2019) Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 393(10183):1819–1830

Article  CAS  PubMed  Google Scholar 

Herbst RS, Giaccone G, de Marinis F et al (2020) Atezolizumab for First-Line treatment of PD-L1-Selected patients with NSCLC. N Engl J Med 383(14):1328–1339

Article  CAS  PubMed  Google Scholar 

Gandhi L, Rodríguez-Abreu D, Gadgeel S et al (2018) Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med 378(22):2078–2092

Article  CAS  PubMed  Google Scholar 

Paz-Ares L, Luft A, Vicente D et al (2018) Pembrolizumab plus Chemotherapy for squamous non-small-cell Lung Cancer. N Engl J Med 379(21):2040–2051

Article  CAS  PubMed  Google Scholar 

Socinski MA, Jotte RM, Cappuzzo F et al (2018) Atezolizumab for First-Line treatment of metastatic nonsquamous NSCLC. N Engl J Med 378(24):2288–2301

Article  CAS  PubMed  Google Scholar 

Jotte R, Cappuzzo F, Vynnychenko I et al (2020) Atezolizumab in Combination with Carboplatin and Nab-Paclitaxel in Advanced squamous NSCLC (IMpower131): results from a Randomized Phase III Trial. J Thorac Oncol 15(8):1351–1360

Article  CAS  PubMed  Google Scholar 

Liao W, Lin JX, Leonard WJ (2013) Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 38(1):13–25

Article  CAS  PubMed  PubMed Central  Google Scholar 

Malek TR, Castro I (2010) Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity 33(2):153–165

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heaney ML, Golde DW (1998) Soluble receptors in human disease. J Leukoc Biol 64(2):135–146

Article  CAS  PubMed  Google Scholar 

Dejica D (2001) Serum soluble IL-2 receptor as a marker of lymphocyte activation in some autoimmune diseases. Effect of immunosuppressive therapy. Roum Arch Microbiol Immunol 60(3):183–201

CAS  PubMed  Google Scholar 

Correia O, Delgado L, Roujeau JC et al (2002) Soluble interleukin 2 receptor and interleukin 1alpha in toxic epidermal necrolysis: a comparative analysis of serum and blister fluid samples. Arch Dermatol 138(1):29–32

Article  CAS  PubMed  Google Scholar 

Gundlach E, Hoffmann MM, Prasse A et al (2016) Interleukin-2 receptor and angiotensin-converting enzyme as markers for ocular sarcoidosis. PLoS ONE 11(1):e0147258

Article  PubMed  PubMed Central  Google Scholar 

Cabrera R, Ararat M, Cao M et al (2010) Hepatocellular carcinoma immunopathogenesis: clinical evidence for global T cell defects and an immunomodulatory role for soluble CD25 (sCD25). Dig Dis Sci 55(2):484–495

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lindqvist CA, Christiansson LH, Simonsson B et al (2010) T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies. Immunology 131(3):371–376

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pedersen AE, Lauritsen JP (2009) CD25 shedding by human natural occurring CD4 + CD25 + regulatory T cells does not inhibit the action of IL-2. Scand J Immunol 70(1):40–43

Article  CAS  PubMed  Google Scholar 

Diem S, Schmid S, Krapf M et al (2017) Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer 111:176–181

Article  PubMed  Google Scholar 

Adachi Y, Tamiya A, Taniguchi Y et al (2020) Predictive factors for progression-free survival in non-small cell lung cancer patients receiving nivolumab based on performance status. Cancer Med 9(4):1383–1391

Article  CAS  PubMed  Google Scholar 

Jiang M, Peng W, Pu X et al (2020) Peripheral blood biomarkers Associated with Outcome in Non-small Cell Lung Cancer Patients treated with Nivolumab and Durvalumab Monotherapy. Front Oncol 10:913

Article  PubMed  PubMed Central  Google Scholar 

Agulló-Ortuño MT, Gómez-Martín Ó, Ponce S et al (2020) Blood predictive biomarkers for patients with non-small-cell Lung Cancer Associated with Clinical Response to Nivolumab. Clin Lung Cancer 21(1):75–85

Article  PubMed  Google Scholar 

Kazandjian D, Gong Y, Keegan P et al (2019) Prognostic value of the lung Immune Prognostic Index for Patients treated for metastatic non-small cell Lung Cancer. JAMA Oncol 5(10):1481–1485

Article  PubMed  PubMed Central  Google Scholar 

Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48(3):452–458

Article  CAS  PubMed  Google Scholar 

Fehniger TA, Cooper MA, Caligiuri MA (2002) Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine Growth Factor Rev 13(2):169–183

Article  CAS  PubMed  Google Scholar 

Rubin LA, Kurman CC, Fritz ME et al (1985) Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 135(5):3172–3177

Article  CAS  PubMed  Google Scholar 

Bien E, Balcerska A (2008) Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review. Biomarkers 13(1):1–26

Article  CAS  PubMed  Google Scholar 

Burton J, Kay NE (1994) Does IL-2 receptor expression and secretion in chronic B-cell leukemia have a role in down-regulation of the immune system? Leukemia 8(1):92–96

CAS  PubMed  Google Scholar 

Yang ZZ, Grote DM, Ziesmer SC et al (2011) Soluble IL-2Rα facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-hodgkin lymphoma. Blood 118(10):2809–2820

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cabrera R, Ararat M, Eksioglu EA et al (2010) Influence of serum and soluble CD25 (sCD25) on regulatory and effector T-cell function in hepatocellular carcinoma. Scand J Immunol 72(4):293–301

Article  CAS  PubMed  PubMed Central  Google Scholar 

Waldmann TA (1990) The multichain interleukin 2 receptor. A target for immunotherapy in lymphoma, autoimmune disorders, and organ allografts [clinical reference]. JAMA 263(2):272–274

Article  CAS  PubMed  Google Scholar 

Jobin N, Garrel D, Bernier J (2000) Increased serum-soluble interleukin-2 receptor in burn patients: characterization and effects on the immune system. Hum Immunol 61(3):233–246

Article  CAS  PubMed  Google Scholar 

Ennishi D, Yokoyama M, Terui Y et al (2009) Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy. Ann Oncol 20(3):526–533

Article  CAS  PubMed  Google Scholar 

Gupta M, Stenson M, O’Byrne M et al (2016) Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2Rα as predictors of event-free survival in T-cell lymphoma. Ann Oncol 27(1):165–172

Article  CAS